Inactive Instrument

Kolinpharma S.p.A.

KIP

IT0005322950

Kolinpharma S.p.A. has completed an IPO in the amount of €3.129 million.

March 08, 2018 at 10:30 am IST

Kolinpharma S.p.A. has completed an IPO in the amount of €3.129 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 447,000 PriceRange: €7 Transaction Features: Regulation S

Latest news about Kolinpharma S.p.A.

Kolinpharma presents supplement; patent application already filed	30/23/30	AN
Kolinpharma increases turnover in the first half of the year	28/23/28	AN
Igea Holding raises offer to take over Kolinpharma shares	28/23/28	AN
Kolinpharma suspends buyback plan after takeover bid by Igea Holding	28/23/28	AN
Kolinpharma S.p.A.'s Equity Buyback announced on May 15, 2023, has suspended.	28/23/28	CI
Kolinpharma continues with share buyback	22/23/22	AN
Kolinpharma S.p.A. commences an Equity Buyback Plan under the authorization approved on April 21, 2023.	15/23/15	CI
Kolinpharma, over 200,000 medical prescriptions in first quarter	04/23/04	AN
Kolinpharma, shareholders' meeting confirms board of directors	21/23/21	AN
Kolinpharma S.p.A.'s Equity Buyback announced on April 28, 2022, has expired.	21/23/21	CI
Europeans up; Tenaris at bottom on Mib.	14/23/14	AN
Kolinpharma, profit halves in 2022 but revenue rises	22/23/22	AN
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	22/23/22	CI
Kolinpharma, prescriptions and whistleblowers grow in fourth quarter	07/23/07	AN
Kolinpharma goes ahead with buybacks of its own common stock	17/23/17	AN
Kolinpharma goes ahead with share buybacks	11/23/11	AN
Kolinpharma purchased its own shares for EUR22,000 approx.	10/23/10	AN
Kolinpharma purchased its own shares for EUR22,000 approx.	10/23/10	AN
Kolinpharma purchased its own shares for about EUR19,000	28/22/28	AN
Kolinpharma S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Kolinpharma S.p.A.'s Equity Buyback announced on February 25, 2022, has expired.	28/22/28	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 28, 2022.	28/22/28	CI
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	29/22/29	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 29, 2021.	25/22/25	CI
Kolinpharma S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2021	28/21/28	CI

Chart Kolinpharma S.p.A.

Duration

Period

More charts

Company Profile

Kolinpharma SpA is an Italy-based company specialized in the pharmaceutical industry. The Company offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+37.78%	71TCr
NOVO NORDISK A/S	+32.82%	58TCr
JOHNSON & JOHNSON	-3.51%	36TCr
MERCK & CO., INC.	+19.94%	33TCr
ABBVIE INC.	+5.14%	29TCr
ASTRAZENECA PLC	+16.64%	24TCr
ROCHE HOLDING AG	-4.13%	21TCr
NOVARTIS AG	+10.63%	21TCr
AMGEN INC.	+9.32%	17TCr

Other Pharmaceuticals